Proscia Wins Fast Company’s Next Big Things in Tech Award
Proscia: Rewiring cancer diagnosis through digitization and AI to improve patient outcomes
Philadelphia – November 20, 2024 – Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, was named to Fast Company’s fourth annual Next Big Things in Tech list honoring emerging technology that has profound impact for industries—from health and sustainability to robotics and artificial intelligence. Its Concentriq software platform was highlighted in the Health category.
This recognition comes as the global cancer burden is newly expected to increase by 77% to 35.3 million cases by 2050¹ amid an intensifying shortage of pathologists. Pathology, the last major field of medicine to go digital, is driving efficiency gains to overcome this supply and demand challenge while advancing a new wave of precision medicine. Each image generated in the shift away from the microscope contains billions of pixels providing one of the most detailed and direct profiles of diseases like cancer that can accelerate the next precision therapies and diagnostics and inform up to 70% of clinical decisions².
“Almost everyone, if not everyone, has been impacted by diseases like cancer,” said Proscia’s CEO David West. “We are proud to be recognized for transforming the way that patients are diagnosed and treated to improve outcomes. Fast Company is one of the most respected voices on innovative technology, and this award validates the impact our software will continue to make in the era of precision medicine.”
Proscia’s Concentriq is an enterprise pathology platform that shifts the standard from microscope to data-rich images and enables the use of AI to unlock new insights from pathology data. Trusted by more than 12,000 pathologists and scientists, it is used by 14 of the top 20 pharmaceutical companies and major diagnostic laboratories around the world.
“The Next Big Things in Tech provides a fascinating glimpse at near- and long-term technological breakthroughs across a variety of sectors,” says Brendan Vaughan, editor-in-chief of Fast Company. “Spanning everything from semiconductors to agricultural gene editing, the companies featured in this year’s list are tackling some of the world’s most pressing and vexing problems.”
This year, Fast Company featured 138 technologies developed by established companies, startups, or research teams for their potential to revolutionize the lives of consumers, businesses, and society overall. Proscia was selected from more than 1,300 nominees and listed alongside companies including Amazon, Databricks, and Waymo.
View the full Next Big Things in Tech list here.
About Fast Company
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. The editor-in-chief is Brendan Vaughan. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication, Inc., and can be found online at fastcompany.com.
About Proscia
Proscia is a software company accelerating pathology’s transition to a digital, data-driven discipline and enabling AI to advance precision medicine. Its Concentriq enterprise pathology platform, precision medicine AI portfolio, and real-world data fuel the development and use of novel therapies and diagnostics to drive the fight against humanity’s most challenging diseases, like cancer. 14 of the top 20 pharmaceutical companies and a global network of diagnostic laboratories rely on Proscia’s solutions each day. The company has FDA 510(k) clearance and CE-IVDR certification for its diagnostic software.. For more information, visit proscia.com, and follow Proscia on LinkedIn and X.
¹ Bizuayehu HM, Ahmed KY, Kibret GD, et al. Global Disparities of Cancer and Its Projected Burden in 2050. JAMA Netw Open. 2024;7(11):e2443198. doi:10.1001/jamanetworkopen.2024.43198
² NHS England (2017). Digital First: Clinical Transformation Through Pathology Innovation. National Pathology Programme; doi: https://www.england.nhs.uk/wp-content/uploads/2014/02/pathol-dig-first.pdf
SOURCE: Proscia
